Brief: Nicox To Get USD 2 Mln Advance Payment From Ocumension Under Zerviate Agreement

Ocumension Therapeutics

05/07/2021 06:41

July 5 (Reuters) - NICOX SA  NCOX.PA :
    * TO RECEIVE $2 MILLION FROM OCUMENSION THERAPEUTICS
 1477.HK  AS
ADVANCE MILESTONE PAYMENT UNDER ZERVIATE® AGREEMENT
    * AMENDMENTS WERE MADE TO CERTAIN RIGHTS UNDER NON-FINANCIAL
CLAUSES OF AGREEMENT
    * REMAINS ELIGIBLE TO RECEIVE SAME SALES MILESTONES OF UP TO
US$17.2 MILLION TOGETHER WITH TIERED ROYALTIES OF BETWEEN 5% AND
9% OF NET SALES OF ZERVIATE BY OCUMENSION
    * ZERVIATE IS CURRENTLY BEING EVALUATED IN A CONFIRMATORY
PHASE 3
CLINICAL TRIAL IN CHINA BY OCUMENSION, TO SUPPORT A CHINESE NEW
DRUG APPLICATION FOR TREATMENT OF OCULAR ITCHING ASSOCIATED WITH
ALLERGIC CONJUNCTIVITIS

Source text for Eikon:  ID:nGNE6R4NLn 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))